Abstract Spinocerebellar ataxia type 3 (SCA3), also known as Machado–Joseph disease (MJD), is a neurodegenerative disorder caused by a polyglutamine expansion in the ATXN3 …
KH Yap, S Azmin, J Che Hamzah, N Ahmad… - Journal of …, 2022 - Springer
Spinocerebellar ataxias (SCA) comprise a rare, genetic subgroup within the degenerative ataxias and are dominantly inherited, with up to 48 recognized genetic subtypes. While an …
H Sarva, VL Shanker - Movement disorders clinical practice, 2014 - Wiley Online Library
The etiology of cerebellar ataxia (CA) is heterogeneous and includes easily identified and often reversible causes (ie, drug toxicity and vitamin B12 deficiency) as well as irreversible …
JAM Saute, LB Jardim - Expert Opinion on Orphan Drugs, 2015 - Taylor & Francis
Introduction: Spinocerebellar ataxia (SCA) type 3/Machado–Joseph disease (SCA3/MJD) is the most common SCA worldwide. SCA3/MJD is an adult onset cerebellar ataxia associated …
N Mendonça, MC França, AF Gonçalves… - Polyglutamine …, 2018 - Springer
Machado-Joseph disease (MJD) also known as Spinocerebellar ataxia type 3, is a hereditary neurodegenerative disease associated with severe clinical manifestations and …
Abstract Machado-Joseph disease (MJD), also known as Spinocerebellar Ataxia type 3 (SCA3), is the most common autosomal dominant ataxia worldwide. MJD integrates a large …
A Neves-Carvalho, S Duarte-Silva… - Expert Opinion on …, 2020 - Taylor & Francis
Introduction Six of the most frequent dominantly inherited spinocerebellar ataxias (SCAs) worldwide–SCA1, SCA2, SCA3, SCA6, SCA7, and SCA17–are caused by an expansion of a …
BR Underwood, DC Rubinsztein - The Cerebellum, 2008 - Springer
Six of the spinocerebellar ataxias (SCAs) are caused by expanded CAG trinucleotide repeats encoding polyglutamine tracts in different genes. Together with three other …
N García Sánchez, E Ugarte Carro… - BMC Medical Informatics …, 2024 - Springer
Motivation Drug repurposing speeds up the development of new treatments, being less costly, risky, and time consuming than de novo drug discovery. There are numerous …